Dimethyl Fumarate Named Allergen of the Year

DAMIAN McNAMARA

doi:10.1016/s0037-6337(11)70097-3

Dimethyl fumarate (DMF) inhibits migration and proliferation of hepatocellular carcinoma (HCC)

10.1055/s-0039-3402232 ◽

2020 ◽

Author(s):

M Michalski ◽

O Wiesner ◽

M Müller-Schilling ◽

K Gülow

Keyword(s):

Hepatocellular Carcinoma ◽

Dimethyl Fumarate

Dimethyl fumarate attenuates working memory deficits in both young and old rats in the streptozotocin-induced model of sporadic Alzheimer’s disease

10.26226/morressier.5785edcfd462b80296c99f5f ◽

2016 ◽

Author(s):

Ewelina Kurowska

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Working Memory ◽

Dimethyl Fumarate ◽

Memory Deficits ◽

Sporadic Alzheimer’S Disease ◽

Old Rats

Delayed-release dimethyl fumarate demonstrated no evidence of difference in clinical outcomes vs fingolimod in patients with RRMS: a propensity-matched comparative effectiveness analysis of the German NeuroTransData registry

10.26226/morressier.59a3eda8d462b8028d895362 ◽

2017 ◽

Author(s):

Stefan Braune

Keyword(s):

Clinical Outcomes ◽

Comparative Effectiveness ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Effectiveness Analysis ◽

Comparative Effectiveness Analysis

Efficacy of Delayed-release Dimethyl Fumarate in Newly Diagnosed Patients With Relapsing-Remitting Multiple Sclerosis: Eight-Year Follow-up of an Integrated Analysis of DEFINE, CONFIRM, and ENDORSE

10.26226/morressier.59a3eda8d462b8028d895222 ◽

2017 ◽

Cited By ~ 1

Author(s):

Ralf Gold

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Integrated Analysis ◽

Newly Diagnosed ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

An Evaluation of Adherence Using Panel Survey Data From Patients With Multiple Sclerosis Treated With Subcutaneous Interferon β-1a or Dimethyl Fumarate

10.26226/morressier.59a3edacd462b8028d895802 ◽

2017 ◽

Author(s):

Amy Perrin Ross

Keyword(s):

Multiple Sclerosis ◽

Survey Data ◽

Dimethyl Fumarate ◽

Panel Survey ◽

Interferon Β ◽

Panel Survey Data

Effectiveness of Dimethyl Fumarate on Disease Activity and Patient-Reported Outcomes in French Subjects with Relapsing-Remitting Multiple Sclerosis in the Real-World: A Subgroup Analysis of PROTEC

10.26226/morressier.59a3edabd462b8028d8950aa ◽

2017 ◽

Author(s):

Zeynep ['Brochet']

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Real World ◽

Subgroup Analysis ◽

Patient Reported Outcomes ◽

Dimethyl Fumarate ◽

The Real ◽

Patient Reported ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis

Teriflunamide and dimethyl fumarate: results from clinical practice

10.26226/morressier.59a3e8b6d462b8028d895231 ◽

2017 ◽

Author(s):

Carlota Cunha

Keyword(s):

Clinical Practice ◽

Dimethyl Fumarate

Delayed-release Dimethyl Fumarate Demonstrated No Difference in Clinical Outcomes versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Real-world EFFECT Study

10.26226/morressier.59a3e8b6d462b8028d8951f5 ◽

2017 ◽

Cited By ~ 1

Author(s):

Jacob Sloane

Keyword(s):

Multiple Sclerosis ◽

Clinical Outcomes ◽

Real World ◽

Dimethyl Fumarate ◽

Effect Study ◽

The Real ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Lymphocyte Decline and Reconstitution after Discontinuation in Patients with Severe, Prolonged Lymphopenia Treated with Delayed-release Dimethyl Fumarate

10.26226/morressier.59a3eda9d462b8028d89542a ◽

2017 ◽

Author(s):

Robert J. Fox

Keyword(s):

Dimethyl Fumarate ◽

Delayed Release

1 year-healthy outcomes in RRMS patients treated with teriflunomied and dimethyl fumarate

10.26226/morressier.5b719e475aff74008ae4cc45 ◽

2018 ◽

Author(s):

Ines González-Suárez

Keyword(s):

Dimethyl Fumarate